B
Bull
Bull · 25%LENZ
$37.95
Szenariopreis
$5.230
+0.020 (+0.38%)Zum Schluss
Loading chart…
- High
- 5.305
- Open
- 5.170
- VWAP
- 5.18
- Vol
- 603.99K
- Mkt Cap
- —
- Low
- 5.000
- Amount
- 3.13M
- EV/EBITDA, TTM
- -0.50
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
AI analysis of LENZ Therapeutics Inc (LENZ)
holdLENZ Therapeutics Inc is currently not a strong buy due to its high volatility and recent downgrades from analysts. The current price is $5.11, which is significantly lower than its 52-week high of $50.40, indicating a substantial decline of 89.87%. Additionally, the stock has a negative forward P/E ratio and has experienced a year-to-date change of -68.06%. The main risk is the recent downgrade from BofA, which reduced the price target from $31 to $7, reflecting concerns about the slower-than-expected launch of its VIZZ product.
Bewertungskennzahlen
The current forward P/E ratio for LENZ Therapeutics Inc (LENZ) is 0.00, compared to its 5-year average forward P/E of -10.36.
Alphio AI Price Scenarios for LENZ
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LENZ
Event-Zeitleiste
News
2.007-14NASDAQ.COMLenz Therapeutics Shares Enter Oversold Territory
8.507-06NewsfilterLENZ Launches Telehealth Platform for VIZZ
- 7.506-24Newsfilter
LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand
8.506-12NASDAQ.COMBiotech Sector Sees Surge in FDA and Global Approvals
- 7.506-08NASDAQ.COM
LENZ Partners with Everest for VIZZ Development in Greater China
LENZ FAQ — answered by Alphio AI
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
LENZ Therapeutics Inc is currently not a strong buy due to its high volatility and recent downgrades from analysts. The current price is $5.11, which is significantly lower than its 52-week high of $50.40, indicating a substantial decline of 89.87%. Additionally, the stock has a negative forward P/E ratio and has experienced a year-to-date change of -68.06%. The main risk is the recent downgrade from BofA, which reduced the price target from $31 to $7, reflecting concerns about the slower-than-expected launch of its VIZZ product.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.